Caliway Biopharmaceuticals Co., Ltd. (6919.TWO)
TWD 571.0
(-2.89%)
TWD 571.0
(-2.89%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -423.93 Million | -242.76 Million | -110.69 Million | -47.23 Million | -106.53 Million |
| Net Income | -488.45 Million | -286.15 Million | -224.26 Million | -98.4 Million | -121.83 Million |
| Depreciation & Amortization | 27.86 Million | 25.33 Million | 23.27 Million | 18.2 Million | 22.47 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 22.97 Million | 19.7 Million | 74.75 Million | 8.27 Million | 31 Thousand |
| Change in working capital | 14.02 Million | -1.39 Million | 18.84 Million | 23.9 Million | -10.67 Million |
| Other non-cash items | -16.91 Million | -4.52 Million | 2.8 Million | 4.47 Million | 3.46 Million |
| Investing Cash Flow | 157.09 Million | -470.54 Million | -14.9 Million | -2.3 Million | -13.39 Million |
| Investments in PPE | -9.68 Million | -14.16 Million | -14.9 Million | -2.3 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | -456.17 Million | - | - | - |
| Sales/Maturities of investments | 166.77 Million | - | - | - | - |
| Other Investing Activities | 5000.00 | -204 Thousand | - | -2.3 Million | 150 Thousand |
| Financing Cash Flow | 3.03 Billion | 771.72 Million | 626.8 Million | 122.73 Million | 103.86 Million |
| Debt repayment | -8.22 Million | -4.72 Million | -87.19 Million | -18.2 Million | -98.86 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | -91 Thousand | - | - |
| Common Stock Issuance | 3.04 Billion | 784.31 Million | 720.88 Million | 126.78 Million | - |
| Other Financing Activities | 3.04 Billion | 784.31 Million | 720.88 Million | 20.65 Million | 5 Million |
| Accounts receivables | -4.77 Million | -3.12 Million | - | 3.2 Million | -3.2 Million |
| Accounts payables | - | - | - | - | - |
| Inventory | 1.78 Million | -2.76 Million | 2.48 Million | -2.5 Million | 428 Thousand |
| Other working capital | 21.31 Million | -2.21 Million | 16.76 Million | 23.51 Million | -7.89 Million |
| Cash at beginning of period | 655.05 Million | 594.9 Million | 93.55 Million | 21.68 Million | 37.47 Million |
| Cash at end of period | 3.42 Billion | 655.05 Million | 594.9 Million | 93.55 Million | 21.68 Million |
| Capital Expenditure | -9.68 Million | -14.16 Million | -14.9 Million | -2.3 Million | - |
| Effect of forex changes on cash | 320 Thousand | 1.73 Million | 137 Thousand | -1.32 Million | 275 Thousand |
| Net cash flow / Change in cash | 2.76 Billion | 60.14 Million | 501.34 Million | 71.86 Million | -15.78 Million |
| Free Cash Flow | -433.62 Million | -256.92 Million | -125.59 Million | -49.54 Million | -106.53 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -176.65 Million | -218.47 Million | -113.65 Million | -488.45 Million | -113.65 Million | -165.99 Million |
| Depreciation & Amortization | 7.24 Million | 7.21 Million | 7.09 Million | 27.86 Million | 7.09 Million | 6.85 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 3.95 Million | 4.95 Million | 5.75 Million | 22.97 Million | 5.75 Million | 5.44 Million |
| Change in working capital | -33.52 Million | 45.76 Million | 9.94 Million | 14.02 Million | 9.94 Million | 10.83 Million |
| Other non-cash items | -14.32 Million | -4.67 Million | -3.79 Million | -16.91 Million | -3.79 Million | -4.97 Million |
| Investing Cash Flow | -407.06 Million | -905 Thousand | 41.29 Million | 157.09 Million | 41.29 Million | -2.67 Million |
| Investments in PPE | -7.06 Million | -905 Thousand | -3.31 Million | -9.68 Million | -3.31 Million | -676 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | 289.4 Million | - | - | 166.77 Million | - | -2 Million |
| Other Investing Activities | -400.33 Million | -246 Thousand | 44.61 Million | 5000.00 | 44.61 Million | -2 Million |
| Financing Cash Flow | -2.13 Million | -1.12 Million | 1.51 Billion | 3.03 Billion | 1.51 Billion | -2.05 Million |
| Debt repayment | -2.13 Million | -2.08 Million | - | -8.22 Million | - | -2.04 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 960 Thousand | - | 3.04 Billion | - | - |
| Other Financing Activities | - | 960 Thousand | 1.51 Billion | 3.04 Billion | 1.51 Billion | - |
| Accounts receivables | -2.02 Million | 5.39 Million | -859.5 Thousand | -4.77 Million | -859.5 Thousand | -3.95 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -4.18 Million | -447 Thousand | 1.14 Million | 1.78 Million | 1.14 Million | -1.14 Million |
| Other working capital | -34.23 Million | 39.32 Million | 9.65 Million | 21.31 Million | 9.65 Million | 11.95 Million |
| Cash at beginning of period | 3.25 Billion | 3.42 Billion | - | 655.05 Million | 490.71 Million | 638.12 Million |
| Cash at end of period | 2.65 Billion | 3.25 Billion | 1.46 Billion | 3.42 Billion | 1.46 Billion | 490.71 Million |
| Capital Expenditure | -7.06 Million | -905 Thousand | -3.31 Million | -9.68 Million | -3.31 Million | -676 Thousand |
| Effect of forex changes on cash | 389 Thousand | -112 Thousand | 238 Thousand | 320 Thousand | 238 Thousand | 193 Thousand |
| Net cash flow / Change in cash | -609.41 Million | -162.36 Million | 1.46 Billion | 2.76 Billion | 975 Million | -147.41 Million |
| Free Cash Flow | -207.66 Million | -161.13 Million | -97.98 Million | -433.62 Million | -97.98 Million | -143.55 Million |
NVA
SUN
APGO
RF-PE
WCN
HOVE